Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
J Gastroenterol
    September 2026
  1. TSURUTA Y, Furuta Y, Nakashima M, Pan C, et al
    Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis.
    J Gastroenterol. 2026 Sep 28. doi: 10.1007/s00535-026-02506.
    >> Share

    August 2026
  2. CHEN M, Gao X, Watanabe K, Fujii T, et al
    Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.
    J Gastroenterol. 2026 Aug 30. doi: 10.1007/s00535-026-02509.
    >> Share

  3. YIN Y, Wang X, Ou D, Zhou Z, et al
    Multimodal MRI reveals glymphatic system activity associated with systemic inflammation and neuropsychiatric symptoms in Crohn's disease.
    J Gastroenterol. 2026 Aug 16. doi: 10.1007/s00535-026-02505.
    >> Share

  4. JOMAA A, Bshara R, Alani M, Ismail B, et al
    S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.
    J Gastroenterol. 2026 Aug 2. doi: 10.1007/s00535-026-02485.
    >> Share

    July 2026
  5. OHNO M, Nishida A, Yoshida S, Yokota Y, et al
    Impact of 5-aminosalicylic acid intolerance on progression to difficult-to-treat ulcerative colitis: a retrospective cohort study.
    J Gastroenterol. 2026 Jul 28. doi: 10.1007/s00535-026-02486.
    >> Share

  6. XU W, Wang W, Song L
    Letter to the Editor to "Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease".
    J Gastroenterol. 2026 Jul 16. doi: 10.1007/s00535-026-02483.
    >> Share

    June 2026
  7. TAKIKAWA T, Kakuta Y, Kikuta K, Haruyama S, et al
    Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.
    J Gastroenterol. 2026 Jun 29. doi: 10.1007/s00535-026-02476.
    >> Share

  8. PENG R, Lin L, Ye C
    Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.
    J Gastroenterol. 2026 Jun 19. doi: 10.1007/s00535-026-02466.
    >> Share

  9. ZHANG X, Zhu J, Wei F, Bu L, et al
    Regulatory mechanism of the RNF168-SCCA1-MYH9 signaling axis in the response of ulcerative colitis.
    J Gastroenterol. 2026 Jun 17. doi: 10.1007/s00535-026-02458.
    >> Share

    May 2026
  10. FAN X, Zhang G
    Comment on "Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease": treatment comparison or treatment sequencing?
    J Gastroenterol. 2026 May 27. doi: 10.1007/s00535-026-02451.
    >> Share

  11. CHENG W
    Comment on "Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan".
    J Gastroenterol. 2026 May 21. doi: 10.1007/s00535-026-02450.
    >> Share

  12. HORIUCHI I, Horiuchi A, Sugimoto K
    Selective IL-23 inhibitors in ulcerative colitis: current evidence and perspectives for multimodal personalized treatment: a narrative review.
    J Gastroenterol. 2026 May 2. doi: 10.1007/s00535-026-02429.
    >> Share

    April 2026
  13. AKIYAMA S, Tsuchiya K
    Reply to "Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis"".
    J Gastroenterol. 2026 Apr 25. doi: 10.1007/s00535-026-02427.
    >> Share

  14. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02399.
    >> Share

  15. PU T, Feng R, Wang C, Zhao Y, et al
    Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02398.
    >> Share

  16. LI X, Pan S, Li Q, Yu B, et al
    Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease.
    J Gastroenterol. 2026 Apr 9. doi: 10.1007/s00535-026-02409.
    >> Share

    March 2026
  17. DONG B, Hou L
    Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis".
    J Gastroenterol. 2026 Mar 27. doi: 10.1007/s00535-026-02378.
    >> Share

  18. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    >> Share

  19. TSURUOKA N, Takedomi H, Sakata Y, Fujioka S, et al
    Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.
    J Gastroenterol. 2026 Mar 10. doi: 10.1007/s00535-026-02383.
    >> Share

    February 2026
  20. WANG X, Tu Y, Zhang S, Che T, et al
    Severity of surgical histopathological fibrosis predicted postoperative recurrence in Crohn's disease: a multi-center retrospective cohort study.
    J Gastroenterol. 2026 Feb 26. doi: 10.1007/s00535-026-02374.
    >> Share

  21. OSAKA R, Naito T, Khor SS, Kakuta Y, et al
    HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02354.
    >> Share

    January 2026
  22. FUJIOKA S, Umeno J, Takeda T, Kinjo K, et al
    Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan.
    J Gastroenterol. 2026 Jan 16. doi: 10.1007/s00535-025-02333.
    >> Share

  23. PU T, Feng R, Wang C, Zhao Y, et al
    METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Jan 4. doi: 10.1007/s00535-025-02341.
    >> Share

  24. NAMBU R, Iwama I, Takeuchi I, Hagiwara SI, et al
    Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.
    J Gastroenterol. 2026 Jan 3. doi: 10.1007/s00535-025-02334.
    >> Share

  25. FUKUI S, Kishimoto M, Matsuura M, Sakamoto A, et al
    Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study.
    J Gastroenterol. 2026;61:46-58.
    >> Share

    November 2025
  26. NISAR M, Awan AR, Ahmad A, Saleem H, et al
    Diagnostic accuracy of anti-integrin alphavbeta6 in ulcerative colitis: a diagnostic meta-analysis.
    J Gastroenterol. 2025 Nov 13. doi: 10.1007/s00535-025-02319.
    >> Share

  27. YOSHIDA A, Takagi T, Kawashima K, Moriya K, et al
    Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.
    J Gastroenterol. 2025 Nov 7. doi: 10.1007/s00535-025-02313.
    >> Share

  28. MAUDUIT A, Mas E, Sola-Tapias N, Menard S, et al
    Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.
    J Gastroenterol. 2025;60:1323-1338.
    >> Share

    September 2025
  29. SONG H, Zhou Y, Liu S, Zhang Q, et al
    Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome: the cross-sectional and longitudinal relationship.
    J Gastroenterol. 2025 Sep 28. doi: 10.1007/s00535-025-02304.
    >> Share

  30. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2025 Sep 22. doi: 10.1007/s00535-025-02299.
    >> Share

  31. TSUTSUI A, Murakami Y, Nishiwaki Y, Asakura K, et al
    Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.
    J Gastroenterol. 2025 Sep 2. doi: 10.1007/s00535-025-02295.
    >> Share

    July 2025
  32. AKIYAMA S, Ito Y, Shiroyama M, Suzuki S, et al
    Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I?BRITE cohort study.
    J Gastroenterol. 2025 Jul 8. doi: 10.1007/s00535-025-02279.
    >> Share

  33. ZAKERSKA-BANASZAK O, Ladziak K, Kruszka D, Maciejewski K, et al
    New potential biomarkers of ulcerative colitis and disease course - integrated metagenomic and metabolomic analysis among Polish patients.
    J Gastroenterol. 2025 Jul 4. doi: 10.1007/s00535-025-02280.
    >> Share

  34. KUDO T, Arai K, Iwama I, Hagiwara SI, et al
    Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan.
    J Gastroenterol. 2025 Jul 2. doi: 10.1007/s00535-025-02271.
    >> Share

  35. MORI R, Ogino T, Murakami M, Kayama H, et al
    Group 1 innate lymphoid cells and inflammatory macrophages exacerbate fibrosis in creeping fat through IFN-gamma secretion.
    J Gastroenterol. 2025;60:838-853.
    >> Share

    May 2025
  36. SAWAHASHI M, Kakuta Y, Naito T, Okazaki S, et al
    Autoantibodies against endothelial protein C receptor and integrin alphavbeta6 predict the development of ulcerative colitis.
    J Gastroenterol. 2025 May 15. doi: 10.1007/s00535-025-02263.
    >> Share

  37. JUN YK, Choi Y, Shin CM, Park YS, et al
    Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02244.
    >> Share

    April 2025
  38. MATSUOKA K, Motoya S, Yamamoto T, Matsuura M, et al
    Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.
    J Gastroenterol. 2025 Apr 21. doi: 10.1007/s00535-025-02249.
    >> Share

  39. UENO N, Sakatani A, Ando K, Saito S, et al
    Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.
    J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02248.
    >> Share

    March 2025
  40. OGINO Y, Sadashima K, Yoshida Y, Takedomi H, et al
    Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02235.
    >> Share

  41. AKIYAMA S, Hayashi R, Takasago T, Kusunoki K, et al
    Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.
    J Gastroenterol. 2025 Mar 6. doi: 10.1007/s00535-025-02231.
    >> Share

  42. OKABAYASHI S, Itaya T, Yamazaki H, Yanai R, et al
    Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors.
    J Gastroenterol. 2025;60:285-293.
    >> Share

    February 2025
  43. KIM MK, Shin SH, Lee CH, Kim S, et al
    Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease.
    J Gastroenterol. 2025 Feb 26. doi: 10.1007/s00535-025-02230.
    >> Share

  44. OKITA M, Takenaka K, Hirai F, Ashizuka S, et al
    Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel.
    J Gastroenterol. 2025 Feb 14. doi: 10.1007/s00535-025-02223.
    >> Share

    January 2025
  45. NAGANUMA M, Shiga H, Shimoda M, Matsuura M, et al
    First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
    J Gastroenterol. 2025 Jan 30. doi: 10.1007/s00535-025-02216.
    >> Share

    December 2024
  46. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Publisher Correction: Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203.
    >> Share

  47. NAGANUMA M
    Reply to "Severe ulcerative colitis: diagnostic criteria and therapy".
    J Gastroenterol. 2024 Dec 14. doi: 10.1007/s00535-024-02200.
    >> Share

  48. NISHIOKA K, Ogino H, Ihara E, Chinen T, et al
    Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse.
    J Gastroenterol. 2024 Dec 13. doi: 10.1007/s00535-024-02199.
    >> Share

  49. CHIBA M
    Severe ulcerative colitis: diagnostic criteria and therapy.
    J Gastroenterol. 2024 Dec 11. doi: 10.1007/s00535-024-02198.
    >> Share

  50. XIONG Z, Li X, Xie M, Guo J, et al
    Small extracellular vesicles derived from adipose mesenchymal stem cells alleviate intestinal fibrosis by inhibiting the FAK/Akt signaling pathway via MFGE8.
    J Gastroenterol. 2024;59:1092-1106.
    >> Share

    November 2024
  51. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Nov 28. doi: 10.1007/s00535-024-02176.
    >> Share

  52. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    >> Share

  53. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis.
    J Gastroenterol. 2024 Nov 11. doi: 10.1007/s00535-024-02172.
    >> Share

    September 2024
  54. CHEN G, Wu X, Zhu H, Li K, et al
    Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases.
    J Gastroenterol. 2024 Sep 10. doi: 10.1007/s00535-024-02148.
    >> Share

    July 2024
  55. MASSIRONI S, Furfaro F, Bencardino S, Allocca M, et al
    Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.
    J Gastroenterol. 2024 Jul 9. doi: 10.1007/s00535-024-02130.
    >> Share

    June 2024
  56. TAKAHASHI K, Morita N, Tamano R, Gao P, et al
    Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    J Gastroenterol. 2024 Jun 14. doi: 10.1007/s00535-024-02121.
    >> Share

    May 2024
  57. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2024 May 30. doi: 10.1007/s00535-024-02116.
    >> Share

  58. NAGANUMA M
    Reply to "promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy".
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02113.
    >> Share

  59. CHIBA M, Kimura K
    Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.
    J Gastroenterol. 2024 May 4. doi: 10.1007/s00535-024-02111.
    >> Share

  60. IMAZU N, Torisu T, Yokote A, Umeno J, et al
    Arginase 2 attenuates ulcerative colitis by antioxidant effects of spermidine.
    J Gastroenterol. 2024 May 2. doi: 10.1007/s00535-024-02104.
    >> Share

    April 2024
  61. MAKUUCHI M, Kakuta Y, Umeno J, Fujii T, et al
    Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2024 Apr 8. doi: 10.1007/s00535-024-02099.
    >> Share

    March 2024
  62. HIRAYAMA D, Hyodo S, Morita K, Nakase H, et al
    Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    J Gastroenterol. 2024 Mar 16. doi: 10.1007/s00535-024-02086.
    >> Share

    January 2024
  63. NAGANUMA M, Nakamura N, Kunisaki R, Matsuoka K, et al
    Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
    J Gastroenterol. 2024 Jan 26. doi: 10.1007/s00535-024-02079.
    >> Share

  64. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion.
    J Gastroenterol. 2024 Jan 21. doi: 10.1007/s00535-024-02077.
    >> Share

    November 2023
  65. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Reply to "Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis".
    J Gastroenterol. 2023 Nov 27. doi: 10.1007/s00535-023-02064.
    >> Share

  66. SUN S, Lv B
    The antiferroptotic effect of indigo on ulcerative colitis.
    J Gastroenterol. 2023 Nov 23. doi: 10.1007/s00535-023-02063.
    >> Share

    October 2023
  67. NAGANUMA M, Kobayashi T, Kunisaki R, Matsuoka K, et al
    Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02048.
    >> Share

    August 2023
  68. WATANABE K, Nojima M, Nakase H, Sato T, et al
    Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
    J Gastroenterol. 2023 Aug 10. doi: 10.1007/s00535-023-02029.
    >> Share

    July 2023
  69. PARKES G, Ungaro RC, Danese S, Abreu MT, et al
    Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    J Gastroenterol. 2023 Jul 25. doi: 10.1007/s00535-023-02013.
    >> Share

  70. SAKURAI T, Omori T, Tanaka H, Ito T, et al
    Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn's disease in Japan (SPREAD-J study).
    J Gastroenterol. 2023 Jul 21. doi: 10.1007/s00535-023-02017.
    >> Share

  71. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.
    J Gastroenterol. 2023 Jul 6. doi: 10.1007/s00535-023-02016.
    >> Share

    June 2023
  72. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2023 Jun 23. doi: 10.1007/s00535-023-02005.
    >> Share

  73. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    >> Share

  74. SHINZAKI S, Sato T, Fukui H
    Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.
    J Gastroenterol. 2023;58:598-599.
    >> Share

    May 2023
  75. MATSUOKA K, Fujii T, Okamoto R, Yamada A, et al
    Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
    J Gastroenterol. 2023 May 5. doi: 10.1007/s00535-023-01998.
    >> Share

    April 2023
  76. WATANABE S, Ogasawara N, Kobayashi S, Kirino S, et al
    Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment.
    J Gastroenterol. 2023;58:379-393.
    >> Share

    March 2023
  77. YAMAKAWA T, Kitamoto H, Nojima M, Kazama T, et al
    Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01979.
    >> Share

  78. NAMBU R, Arai K, Kudo T, Murakoshi T, et al
    Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01972.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016